Ironwood(IRWD) - 2025 Q1 - Quarterly Results

Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance – Reiterates 2025 guidance of LINZESS U.S. net sales of $800-$850 million and total Ironwood revenue of $260-290 million – – LINZESS (Iinaclotide) EUTRx prescription demand growth in Q1 2025 of 8% year-over-year; in line with full-year expectations - – Raises adjusted EBITDA to greater than $105 million for 2025 – BOSTON, Mass., April 25, 2025 — Ironwood P ...